Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
- Completion LockedPhase 1NCT07859007A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsInsmed Incorporated · Healthy VolunteersNot yet recruitingINSMLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07928037A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic...Novartis Pharmaceuticals · Metastatic Castration-Resistant Prostate CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06202339Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT).Alpha Tau Medical LTD. · Carcinoma of the VulvaNot yet recruitingDRTSLead
- Enrollment
- Locked
- Primary completion
- Apr 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07336654Circadian Rhythm Monitoring StudyResMed · Circadian RhythmNot yet recruitingRMDLead
- Enrollment
- Locked
- Primary completion
- Oct 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07055295Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis RegimenSinovac Biotech Co., Ltd · RabiesNot yet recruitingSVALead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07914972Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC PatientsAstraZeneca · Non-small Cell Lung CancerNot yet recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07915947LTG-321 - Itraconazole Drug-drug Interaction (DDI) StudyLatigo Biotherapeutics · PK Drug-drug Interaction StudyNot yet recruitingLTGOLead
- Enrollment
- Locked
- Primary completion
- Dec 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07680907A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Janssen-Cilag Farmaceutica Ltda. · Carcinoma, Non-Small-Cell LungNot yet recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07430059Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantVivani Medical, Inc · Obesity & OverweightNot yet recruitingVANILead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07945548A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine...Novartis Pharmaceuticals · Breast CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 1, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07770074A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) PatientsNovartis Pharmaceuticals · Radioiodine-refractory Differentiated Thyroid CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 5, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07908641Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release...Amgen · PsoriasisNot yet recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Jan 10, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07862114A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsGlaxoSmithKline · Healthy ParticipantsNot yet recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Jan 12, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06897527A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)GlaxoSmithKline · Neoplasms, EndometrialNot yet recruitingGSKLead
- Enrollment
- Locked
- Primary completion
- Jan 13, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07600775A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)Merck Sharp & Dohme LLC · Human Immunodeficiency Virus (HIV)Not yet recruitingMRKLead
- Enrollment
- Locked
- Primary completion
- Jan 19, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07726914Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male ParticipantsSanofi · Chronic Graft Versus Host DiseaseNot yet recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Jan 26, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07055893Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis RegimenSinovac Biotech Co., Ltd · Rabies (Healthy Volunteers)Not yet recruitingSVALead
- Enrollment
- Locked
- Primary completion
- Jan 30, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07882576A Study to Evaluate Treatment Patterns and Investigate Adult Patients With B-cell LymphomaAstraZeneca · Lymphoma, B-CellNot yet recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 30, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07896746Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and RwandaNovartis Pharmaceuticals · MalariaNot yet recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 30, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07235397Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National DatasetPfizer · Respiratory Syncytial Virus InfectionsNot yet recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Nov 13, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07279948Lung Cancer Screening Implementation Project in the Brazilian Public Health Care System (LUSIP)AstraZeneca · Lung CancerNot yet recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Jan 31, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07927023A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple MyelomaPfizer · Multiple MyelomaNot yet recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Feb 1, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07742384Study on the Effect of Famotidine on Pharmacokinetics of TaletrectinibNuvation Bio Inc. · Healthy Adult ParticipantsNot yet recruitingNUVBLead
- Enrollment
- Locked
- Primary completion
- Feb 2, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07855991A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic ImpairmentBeOne Medicines · Hepatic ImpairmentNot yet recruitingONCLead
- Enrollment
- Locked
- Primary completion
- Feb 8, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 24 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.